Considering that the effects of anti-angiogenesis treatments on endothelial cells are equivalent for any patient, the different responses to the drugs may be attributed to the genetic variability of tumor cells expressing the target receptors and/or over-activating the mTOR pathway. Here, MTOR is linked to neoplasm.